title: Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials.
abstract: OBJECTIVE
  The purpose of this research was to determine the relative safety and efficacy of multiple (> or =2) overlapping Cypher sirolimus-eluting stents (SES) (Johnson & Johnson, New Brunswick, New Jersey).
  
  
  BACKGROUND
  Overlapping coronary stents are common. The periprocedural and late clinical and angiographic consequences of overlapped coronary stents are not clearly defined, particularly for drug-eluting stents.
  
  
  METHODS
  All patients enrolled into five clinical trials of the SES were analyzed. Three of these trials were prospective randomized comparisons of the SES to the bare-metal stent (BMS), and two were prospective non-randomized trials of SES-treated patients with historical controls. All clinical and angiographic outcomes in overlap-stent-treated patients were compared by stent type and with single-stent-treated patients for the same stent device.
  
  
  RESULTS
  In all, 575 patients with stent overlap (337 SES, 238 BMS) and 1,162 patients with single stents (697 SES, 465 BMS) were analyzed. Stent overlap was associated with a greater late lumen loss in stent and more frequent angiographic restenosis regardless of stent type. Among overlap-stent-treated patients, the SES provided similar magnitude of restenosis benefit as observed for single-stent-treated patients. Overlapped SES was not associated with an increase in myocardial infarction.
  
  
  CONCLUSIONS
  The strategy of SES overlap, when required, is both safe and efficacious in reducing restenosis with no increase in the incidence of myocardial infarction or major adverse cardiovascular events, when compared with a bare metal coronary stent prosthesis.
authors.affiliation: Heart Center of Greater Cincinnati and the Lindner Center for Research and Education at The Christ Hospital, Ohio Heart and Vascular Center Inc., Cincinnati, Ohio 45219, USA. lindner@fuse.net
authors.forename: Dean J
authors.initials: DJ
authors.lastname: Kereiakes
authors.forename: Hong
authors.initials: H
authors.lastname: Wang
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Popma
authors.forename: Richard E
authors.initials: RE
authors.lastname: Kuntz
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Donohoe
authors.forename: Joachim
authors.initials: J
authors.lastname: Schofer
authors.forename: Erick
authors.initials: E
authors.lastname: Schampaert
authors.forename: Bernhard
authors.initials: B
authors.lastname: Meier
authors.forename: Martin B
authors.initials: MB
authors.lastname: Leon
authors.forename: Jeffrey W
authors.initials: JW
authors.lastname: Moses
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D002986:Clinical Trials as Topic; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000517:prevention & control; D023921:Coronary Stenosis / Q000628:therapy; D003331:Coronary Vessels; D003402:Creatine Kinase / Q000097:blood; D006801:Humans; D008670:Metals; D008875:Middle Aged; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents / Q000009:adverse effects*
chemical_list: D008670:Metals; D003402:Creatine Kinase; D020123:Sirolimus